person · Reporting owner

Manning Paul B

Disclosed activity across 8 companies

Tapewire entity: 33957
SEC CIK: 0001494695

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Candel Therapeutics, Inc.CADL · Entity 4969	Director	September 30, 2026	October 02, 2026
Liquidia CorpLQDA · Entity 1860	Director	June 16, 2026	June 18, 2026
Pasithea Therapeutics Corp.KTTA · Entity 7685	10% owner	October 22, 2022	February 14, 2023
Verrica Pharmaceuticals Inc.VRCA · Entity 6823	Director · 10% owner	November 25, 2025	November 26, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Candel Therapeutics, Inc.

Report date September 30, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2036-09-30	Direct	2,189	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 2,189 · Balance 2,189 F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.

Liquidia Corp

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	475,465	Reported balance After 2026-06-16 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 5,882 · Balance 475,465 F1: Represents restricted stock units ("RSUs"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.
Common StockSEC Table I · non-derivative	Direct	3,131,794	Reported balance Holding disclosure · report date 2026-06-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,131,794 F2: The shares are held by Reporting Person jointly with his spouse.
Common StockSEC Table I · non-derivative	IndirectSee footnote	716,311	Reported balance Holding disclosure · report date 2026-06-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 716,311 F3: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	798,335	Reported balance Holding disclosure · report date 2026-06-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 798,335 F4: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	435,674	Reported balance Holding disclosure · report date 2026-06-16 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 435,674 F5: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.
Common StockSEC Table I · non-derivative	IndirectSee footnote	198,413	Reported balance Holding disclosure · report date 2026-06-16 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 198,413 F6: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily, the manager of PD, and has shared voting and investment power with respect to the shares held by PD.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.

F2: The shares are held by Reporting Person jointly with his spouse.

F3: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

F4: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust.

F5: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM.

F6: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily, the manager of PD, and has shared voting and investment power with respect to the shares held by PD.

Pasithea Therapeutics Corp.

Report date October 22, 2022 · Filed February 14, 2023

Jointly reported with PD Joint Holdings, LLC Series 2016-A, Manning Bradford, Tiger Lily Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,608,696	Reported balance Holding disclosure · report date 2022-10-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,608,696
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2027-06-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2022-10-22 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed

Verrica Pharmaceuticals Inc.

Report date November 25, 2025 · Filed November 26, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,958,189	Reported balance After 2025-11-25 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-11-25 · Purchase · Acquired 1,375,380 · Balance 3,958,189 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F2: The shares are held by Mr. Manning jointly with his spouse.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,348,372	Reported balance After 2025-11-25 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2025-11-25 · Purchase · Acquired 2,750,762 · Balance 3,348,372 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	25,663	Reported balance Holding disclosure · report date 2025-11-25 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 25,663 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F6: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.
Series C Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25	Direct	343,845	Reported balance After 2025-11-25 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-11-25 · Purchase · Acquired 343,845 · Balance 343,845 F8: The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7: Immediately exercisable. F2: The shares are held by Mr. Manning jointly with his spouse.
Series C Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25	IndirectSee footnote	687,690	Reported balance After 2025-11-25 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-11-25 · Purchase · Acquired 687,690 · Balance 687,690 F9: The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7: Immediately exercisable. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	89,187	Reported balance Holding disclosure · report date 2025-11-25 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 89,187 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy trust	332,433	Reported balance Holding disclosure · report date 2025-11-25 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 332,433 F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F5: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.

F2: The shares are held by Mr. Manning jointly with his spouse.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB.

F4: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F5: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F6: The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.

F7: Immediately exercisable.

F8: The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

F9: The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Acumen Pharmaceuticals, Inc.

Report date July 06, 2021 · Filed July 08, 2021

Section 16 reporting ended · disclosed 2021-07-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,040,193	Reported balance After 2021-07-06 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-07-06 · Conversion · Acquired 2,950,484 · Balance 3,040,193 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,352,693	Reported balance After 2021-07-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-07-06 · Purchase · Acquired 312,500 · Balance 3,352,693 F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	657,985	Reported balance After 2021-07-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-07-06 · Conversion · Acquired 657,985 · Balance 657,985 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-06 · Conversion · Disposed 1,634,515 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-06 · Conversion · Disposed 1,315,969 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-07-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-06 · Conversion · Disposed 657,985 · Balance 0 F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

Filing footnotes · ownership attribution and instrument terms

F1: On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.

F3: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

AveXis, Inc.

Report date May 15, 2018 · Filed May 15, 2018

Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-05-15 transaction · row 1 1 source row Row 1 · 2018-05-15 · Disposition to issuer · Disposed 228,752 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Includes 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
Common StockSEC Table I · non-derivative	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-05-15 · Disposition to issuer · Disposed 1,201,160 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: These shares are held by PBM Capital Investments, LLC ("PBM"). The Reporting Person has the sole voting and investment power with respect to the shares held by the PBM. The Reporting Person disclaims beneficial ownership of the shares held by PBM except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2018-05-15 · Disposition to issuer · Disposed 25,293 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F4: These shares are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10	Direct	Reported balance After 2018-05-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-05-15 · Disposition to issuer · Disposed 26,496 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30	Direct	Reported balance After 2018-05-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13	Direct	Reported balance After 2018-05-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2025-05-04	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-05-15 · Disposition to issuer · Disposed 137,154 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F6: In connection with the transactions contemplated by the Merger Agreement, the Warrant was canceled in exchange for a lump sum cash payment equal to (i) the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by (ii) the number of shares of Common Stock underlying the Warrant. F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2024-03-07	IndirectBy LLC	Reported balance After 2018-05-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-05-15 · Disposition to issuer · Disposed 103,478 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F8: The amount reported reflects a pro rata distribution to members of PBM on August 15, 2016. In prior reports, the Reporting Person reported beneficial ownership of 130,623 shares of common stock underlying the Warrant. F9: Immediately exercisable. F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.

F2: Includes 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.

F3: These shares are held by PBM Capital Investments, LLC ("PBM"). The Reporting Person has the sole voting and investment power with respect to the shares held by the PBM. The Reporting Person disclaims beneficial ownership of the shares held by PBM except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F4: These shares are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F5: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.

F6: In connection with the transactions contemplated by the Merger Agreement, the Warrant was canceled in exchange for a lump sum cash payment equal to (i) the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by (ii) the number of shares of Common Stock underlying the Warrant.

F7: The Warrant is held by PBM. Mr. Manning has the sole voting and investment power with respect to the shares issuable upon exercise of the Warrant held by PBM. Mr. Manning disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F8: The amount reported reflects a pro rata distribution to members of PBM on August 15, 2016. In prior reports, the Reporting Person reported beneficial ownership of 130,623 shares of common stock underlying the Warrant.

F9: Immediately exercisable.

Dova Pharmaceuticals Inc.

Report date November 12, 2019 · Filed November 12, 2019

Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-12 transaction · row 1 1 source row Row 1 · 2019-11-12 · Other · Disposed 12,979,016 · Balance 0 F1: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.
Common StockSEC Table I · non-derivative	IndirectBy LLC	0	Reported balance After 2019-11-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-11-12 · Other · Disposed 1,783,226 · Balance 0 F2: These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of (i) 12,214,953 shares held directly by Mr. Manning, and (ii) 764,063 shares held by Mr. Manning together with his spouse as Joint Tenants with Right of Survivorship.

F2: These shares are held by BKB Growth Investments, LLC ("BKB"). Manning is a co-manager of BKB and, as such, has unilateral voting and investment power with respect to the shares held by BKB. Manning disclaims beneficial ownership of the shares held by BKB except to the extent of his pecuniary interest therein, and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Taysha Gene Therapies, Inc.

Report date May 30, 2025 · Filed June 04, 2025

Section 16 reporting ended · disclosed 2025-06-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,841,704	Reported balance After 2025-05-30 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2025-05-30 · Purchase · Acquired 750,000 · Balance 2,841,704 F1: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
Common StockSEC Table I · non-derivative	IndirectSee footnote	14,723,948.12	Reported balance Holding disclosure · report date 2025-05-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 14,723,948.12 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F3: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	22,000	Reported balance Holding disclosure · report date 2025-05-30 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 22,000 F4: The shares are held directly by BKB G2 Investments, LLC ("BKB G2"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,013,458.88	Reported balance Holding disclosure · report date 2025-05-30 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 4,013,458.88 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F5: The shares are held directly by The PBM 2023 Grantor Retained Annuity Trust (the "2023 Annuity Trust"). The Reporting Person is the trustee of the 2023 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2023 Annuity Trust.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,000,000	Reported balance Holding disclosure · report date 2025-05-30 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 4,000,000 F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F6: The shares are held directly by The PBM 2025 Grantor Retained Annuity Trust (the "2025 Annuity Trust"). The Reporting Person is the trustee of the 2025 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2025 Annuity Trust.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.

F2: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16.

F3: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust.

F4: The shares are held directly by BKB G2 Investments, LLC ("BKB G2"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB G2, and has shared voting and investment power with respect to the shares held by BKB G2.

F5: The shares are held directly by The PBM 2023 Grantor Retained Annuity Trust (the "2023 Annuity Trust"). The Reporting Person is the trustee of the 2023 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2023 Annuity Trust.

F6: The shares are held directly by The PBM 2025 Grantor Retained Annuity Trust (the "2025 Annuity Trust"). The Reporting Person is the trustee of the 2025 Annuity Trust and has sole voting and investment power with respect to the shares held by the 2025 Annuity Trust.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2026 Filed Oct 2, 2026 21:54 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	2,189	$8.68 Strike: $10.44	$18,991.76	Disclosure SEC source: 0001193125-26-412654 · ownership.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,189 Underlying: Common Stock · 2,189 shares Expires 2036-09-30 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document
June 30, 2026 Filed Jul 1, 2026 20:21 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	2,199	$8.64 Strike: $10.30	$18,997.16	Disclosure SEC source: 0001494695-26-000018 · ownership.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,199 Underlying: Common Stock · 2,199 shares Expires 2036-06-30 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document
June 23, 2026 Filed Jun 24, 2026 20:26 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	32,000	$0.00 Strike: $9.08	$0.00	Disclosure SEC source: 0001494695-26-000015 · ownership.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
June 16, 2026 Filed Jun 18, 2026 20:15 UTC	Liquidia Corp LQDA · Entity 1860	GrantCommon Stock	5,882	$0.00	$0.00	Disclosure SEC source: 0001494695-26-000013 · form4-06182026_040618.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,465 F1 · shares: Represents restricted stock units ("RSUs"). The RSUs convert into common stock on a one-for-one basis and shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:41 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	12,610	$64.42	$812,336.20	Disclosure SEC source: 0001494695-26-000011 · form4-06082026_080604.xml · nonDerivative · entry 5 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 798,335 F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.27 to $64.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:41 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	68,265	$63.83	$4,357,354.95	Disclosure SEC source: 0001494695-26-000011 · form4-06082026_080604.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 810,945 F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.27 to $64.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:41 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	19,125	$62.62	$1,197,607.50	Disclosure SEC source: 0001494695-26-000011 · form4-06082026_080604.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 879,210 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.21 to $63.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by the Paul B. Manning Revocable Trust (the "PBM 2000 Trust"). The Reporting Person is the trustee of the PBM 2000 Trust and has sole voting and investment power with respect to the shares held by the PBM 2000 Trust. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:41 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	88,487	$64.28	$5,687,944.36	Disclosure SEC source: 0001494695-26-000011 · form4-06082026_080604.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 716,311 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.61 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:41 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	11,513	$63.13	$726,815.69	Disclosure SEC source: 0001494695-26-000011 · form4-06082026_080604.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 804,798 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $63.365 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
March 31, 2026 Filed Apr 2, 2026 21:17 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	4,618	$4.11 Strike: $4.90	$18,998.45	Disclosure SEC source: 0001494695-26-000007 · ownership.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,618 Underlying: Common Stock · 4,618 shares Expires 2036-03-31 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document
February 23, 2026 Filed Feb 27, 2026 00:38 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	550,458	$5.45	$2,999,996.10	Disclosure SEC source: 0001193125-26-078246 · ownership.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 2,763,527 F1 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
February 11, 2026 Filed Feb 13, 2026 02:16 UTC	Liquidia Corp LQDA · Entity 1860	OtherCommon Stock	55,116	$42.63	$2,349,595.08	Disclosure SEC source: 0001494695-26-000002 · form4-02132026_020223.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,583 F1 · kind: The Reporting Person withdrew 55,116 shares of the Issuer from PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"), a grantor retained annuity trust, in exchange for cash. The withdrawal of shares resulted in a decrease in the number of shares the Reporting Person beneficially owns indirectly through PBM 2024 GRAT and a corresponding increase in the number of shares the Reporting Person beneficially owns directly. This withdrawal of shares constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934. F1 · balance_after: The Reporting Person withdrew 55,116 shares of the Issuer from PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"), a grantor retained annuity trust, in exchange for cash. The withdrawal of shares resulted in a decrease in the number of shares the Reporting Person beneficially owns indirectly through PBM 2024 GRAT and a corresponding increase in the number of shares the Reporting Person beneficially owns directly. This withdrawal of shares constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934. F3 · balance_after: Includes 375,712 shares distributed to the Reporting Person in satisfaction of annuity obligation from the PBM 2024 GRAT. Read SEC document
February 11, 2026 Filed Feb 13, 2026 02:16 UTC	Liquidia Corp LQDA · Entity 1860	OtherCommon Stock	55,116	$42.63	$2,349,595.08	Disclosure SEC source: 0001494695-26-000002 · form4-02132026_020223.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: The Reporting Person withdrew 55,116 shares of the Issuer from PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"), a grantor retained annuity trust, in exchange for cash. The withdrawal of shares resulted in a decrease in the number of shares the Reporting Person beneficially owns indirectly through PBM 2024 GRAT and a corresponding increase in the number of shares the Reporting Person beneficially owns directly. This withdrawal of shares constitutes a change in form of beneficial ownership of the shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934. F2 · ownership.nature: The shares are held directly by the PBM 2024 GRAT. The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT. Read SEC document
November 25, 2025 Filed Nov 26, 2025 00:00 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseSeries C Warrant (right to buy) · Derivative	687,690	Not disclosed Strike: $6.32	Not disclosed	Disclosure SEC source: 0001494695-25-000004 · form4-11252025_071105.xml · derivative · entry 9 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 687,690 Underlying: Common Stock · 687,690 shares Expires 2030-11-25 F9 · price: The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7 · derivative.exercise_date: Immediately exercisable. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
November 25, 2025 Filed Nov 26, 2025 00:00 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseSeries C Warrant (right to buy) · Derivative	343,845	Not disclosed Strike: $6.32	Not disclosed	Disclosure SEC source: 0001494695-25-000004 · form4-11252025_071105.xml · derivative · entry 8 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,845 Underlying: Common Stock · 343,845 shares Expires 2030-11-25 F8 · price: The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F7 · derivative.exercise_date: Immediately exercisable. F2 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
November 25, 2025 Filed Nov 26, 2025 00:00 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	2,750,762	$4.24	$11,670,107.79	Disclosure SEC source: 0001494695-25-000004 · form4-11252025_071105.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,348,372 F1 · balance_after: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F3 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
November 25, 2025 Filed Nov 26, 2025 00:00 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	1,375,380	$4.24	$5,835,049.65	Disclosure SEC source: 0001494695-25-000004 · form4-11252025_071105.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,958,189 F1 · balance_after: Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. F2 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
September 02, 2025 Filed Sep 2, 2025 23:46 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	74,230	$29.14	$2,163,062.20	Disclosure SEC source: 0001415889-25-023468 · form4-09022025_110909.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 430,828 F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.25 inclusive. F2 · ownership.nature: The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT. Read SEC document
September 02, 2025 Filed Sep 2, 2025 23:46 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	254,038	$28.67	$7,283,269.46	Disclosure SEC source: 0001415889-25-023468 · form4-09022025_110909.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 505,058 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.08 to $29.065 inclusive. F2 · ownership.nature: The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT. Read SEC document
August 29, 2025 Filed Sep 2, 2025 23:46 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	188,232	$27.62	$5,198,967.84	Disclosure SEC source: 0001415889-25-023468 · form4-09022025_110909.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 759,096 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.77 inclusive. F2 · ownership.nature: The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT. Read SEC document
August 28, 2025 Filed Sep 2, 2025 23:46 UTC	Liquidia Corp LQDA · Entity 1860	SaleCommon Stock	154,337	$27.94	$4,312,175.78	Disclosure SEC source: 0001415889-25-023468 · form4-09022025_110909.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 947,328 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.34 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4) and (5). F2 · ownership.nature: The shares are held directly by the PBM 2024 Grantor Retained Annuity Trust (the "PBM 2024 GRAT"). The Reporting Person is the trustee of the PBM 2024 GRAT and has sole voting and investment power with respect to the shares held by the PBM 2024 GRAT. Read SEC document
June 25, 2025 Filed Jun 26, 2025 12:30 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantCommon Stock	1,070,663	$4.67	$4,999,996.21	Disclosure SEC source: 0000950170-25-090197 · ownership.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 2,213,069 F1 · kind: Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. F2 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
June 17, 2025 Filed Jun 18, 2025 12:35 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	14,240	$0.00 Strike: $4.94	$0.00	Disclosure SEC source: 0000950170-25-087702 · ownership.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
June 17, 2025 Filed Jun 20, 2025 20:32 UTC	Liquidia Corp LQDA · Entity 1860	GrantCommon Stock	18,396	$0.00	$0.00	Disclosure SEC source: 0001104659-25-061191 · tm2518541-5_4seq1.xml · nonDerivative · entry 6 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,755 F6 · balance_after: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document
May 30, 2025 Filed Jun 4, 2025 01:38 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	750,000	$2.75	$2,062,500.00	Disclosure SEC source: 0001415889-25-015480 · form4-06042025_010624.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,841,704 F1 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
December 16, 2024 Filed Dec 18, 2024 21:11 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	750,000	$6.00	$4,500,000.00	Disclosure SEC source: 0000950170-24-137889 · ownership.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By BKB Growth Investments, LLC Disclosed balance after: 1,303,752 F2 · ownership.nature: The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
December 16, 2024 Filed Dec 18, 2024 21:11 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	PurchaseCommon Stock	500,000	$6.00	$3,000,000.00	Disclosure SEC source: 0000950170-24-137889 · ownership.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Paul B. Manning Revocable Trust Disclosed balance after: 1,142,406 F1 · ownership.nature: The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document
November 26, 2024 Filed Nov 26, 2024 21:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	GiftCommon Stock	450,000	$0.00	$0.00	Disclosure SEC source: 0001415889-24-027709 · form4-11262024_041101.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,828,094 F2 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
November 22, 2024 Filed Nov 26, 2024 21:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseSeries B Warrants (right to buy) · Derivative	2,247,191	Not disclosed Strike: $1.34	Not disclosed	Disclosure SEC source: 0001415889-24-027709 · form4-11262024_041101.xml · derivative · entry 12 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,247,191 Underlying: Common Stock · 2,247,191 shares Expires 2029-11-22 F3 · price: The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock. F4 · ownership.nature: The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
November 22, 2024 Filed Nov 26, 2024 21:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseSeries A Warrants (right to buy) · Derivative	2,247,191	Not disclosed Strike: $1.07	Not disclosed	Disclosure SEC source: 0001415889-24-027709 · form4-11262024_041101.xml · derivative · entry 11 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,247,191 Underlying: Common Stock · 2,247,191 shares Expires 2025-11-22 F3 · price: The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock. F4 · ownership.nature: The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
November 22, 2024 Filed Nov 26, 2024 21:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseSeries B Warrants (right to buy) · Derivative	9,213,483	Not disclosed Strike: $1.34	Not disclosed	Disclosure SEC source: 0001415889-24-027709 · form4-11262024_041101.xml · derivative · entry 10 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,213,483 Underlying: Common Stock · 9,213,483 shares Expires 2029-11-22 F1 · price: The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F2 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
November 22, 2024 Filed Nov 26, 2024 21:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseSeries A Warrants (right to buy) · Derivative	9,213,483	Not disclosed Strike: $1.07	Not disclosed	Disclosure SEC source: 0001415889-24-027709 · form4-11262024_041101.xml · derivative · entry 9 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,213,483 Underlying: Common Stock · 9,213,483 shares Expires 2025-11-22 F1 · price: The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F2 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
November 22, 2024 Filed Nov 26, 2024 21:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	4,494,382	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027709 · form4-11262024_041101.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,976,101 F3 · price: The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock. F4 · ownership.nature: The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
November 22, 2024 Filed Nov 26, 2024 21:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	18,426,966	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-24-027709 · form4-11262024_041101.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,278,094 F1 · price: The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. F2 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
September 19, 2024 Filed Sep 23, 2024 20:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	GiftCommon Stock	891,870.42	$0.00	$0.00	Disclosure SEC source: 0001415889-24-023835 · form4-09232024_040901.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 891,870.42 F1 · kind: Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024. F2 · ownership.nature: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
September 19, 2024 Filed Sep 23, 2024 20:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	GiftCommon Stock	891,870.42	$0.00	$0.00	Disclosure SEC source: 0001415889-24-023835 · form4-09232024_040901.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 891,870.42 F1 · kind: Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024. F2 · ownership.nature: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
September 19, 2024 Filed Sep 23, 2024 20:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	GiftCommon Stock	891,870.41	$0.00	$0.00	Disclosure SEC source: 0001415889-24-023835 · form4-09232024_040901.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 891,870.41 F1 · kind: Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024. F2 · ownership.nature: These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document
September 19, 2024 Filed Sep 23, 2024 20:15 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	GiftCommon Stock	2,675,611.25	$0.00	$0.00	Disclosure SEC source: 0001415889-24-023835 · form4-09232024_040901.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By GRAT Disclosed balance after: 0 F1 · kind: Upon termination of a Grantor Retained Annuity Trust, 2,675,611.25 shares were transferred to trusts for the benefit of the Reporting Person's immediate family members on September 19, 2024. Read SEC document
September 12, 2024 Filed Sep 16, 2024 20:05 UTC	Liquidia Corp LQDA · Entity 1860	PurchaseCommon Stock	337,078	$8.90	$2,999,994.20	Disclosure SEC source: 0001104659-24-100179 · tm2424167-1_4seq1.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 816,311 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's underwritten public offering of common stock, which closed on September 12, 2024, and such shares of common stock are subject to a lock up agreement between the Reporting Person and BofA Securities, Inc., pursuant to which the shares cannot be sold for 90 days following September 11, 2024. F2 · ownership.nature: The securities are held by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of BKB, and has shared voting and investment power with respect to the shares held by BKB. Read SEC document
June 27, 2024 Filed Jul 1, 2024 12:00 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	1,333,333	$2.25	$2,999,999.25	Disclosure SEC source: 0001415889-24-018515 · form4-07012024_080703.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333,333 Read SEC document
June 26, 2024 Filed Jun 27, 2024 12:37 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	14,240	$0.00 Strike: $5.71	$0.00	Disclosure SEC source: 0000950170-24-078171 · ownership.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
June 20, 2024 Filed Jun 25, 2024 01:39 UTC	Liquidia Corp LQDA · Entity 1860	GrantCommon Stock	20,359	$0.00	$0.00	Disclosure SEC source: 0001104659-24-074473 · tm2418154-6_4seq1.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,689 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. Read SEC document
December 14, 2023 Filed Dec 18, 2023 22:00 UTC	Liquidia Corp LQDA · Entity 1860	PurchaseCommon Stock	279,330	$7.16	$2,000,002.80	Disclosure SEC source: 0001104659-23-126932 · tm2332275-6_4seq1.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,330 F1 · kind: Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's underwritten public offering of common stock, which closed on December 14, 2023, and such shares of common stock are subject to a lock up agreement between the Reporting Person and BofA Securities, Inc.., pursuant to which the shares cannot be sold for 90 days following December 12, 2023. Read SEC document
November 17, 2023 Filed Nov 20, 2023 12:35 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	100,000	$1.63	$163,000.00	Disclosure SEC source: 0001209191-23-055942 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,566,667 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust. Read SEC document
August 16, 2023 Filed Aug 17, 2023 00:57 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	16,466,667	$0.90	$14,820,000.30	Disclosure SEC source: 0001209191-23-046154 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,466,667 F1 · balance_after: The change in the total shares held prior to the transactions reported herein reflects a change in form of ownership and, therefore, was not required to be reported pursuant to Section 16. F2 · ownership.nature: The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Revocable Trust"). The Reporting Person is the trustee of the Revocable Trust and has sole voting and investment power with respect to the shares held by the Revocable Trust. Read SEC document
July 24, 2023 Filed Jul 24, 2023 22:47 UTC	Verrica Pharmaceuticals Inc. VRCA · Entity 6823	PurchaseCommon Stock	200,000	$5.02	$1,004,000.00	Disclosure SEC source: 0001209191-23-043255 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,851,128 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.75 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Reflects the Reporting Person's contribution of shares into the PBM 2022 Grantor Retained Annuity Trust. This transfer of shares constitutes a change in the form of beneficial ownership and was exempt from reporting. F3 · ownership.direct: The shares are held by Mr. Manning jointly with his spouse. Read SEC document
June 28, 2023 Filed Jun 29, 2023 13:00 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	14,240	$0.00 Strike: $1.22	$0.00	Disclosure SEC source: 0001209191-23-040134 · doc4.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2033-06-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document
June 19, 2023 Filed Jun 21, 2023 21:01 UTC	Liquidia Corp LQDA · Entity 1860	GrantNon-Qualified Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $8.63	$0.00	Disclosure SEC source: 0001104659-23-073393 · tm2317720-7_4seq1.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-19 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 19, 2026. Read SEC document
October 31, 2022 Filed Nov 2, 2022 20:09 UTC	Taysha Gene Therapies, Inc. TSHA · Entity 4549	PurchaseCommon Stock	1,500,000	$2.00	$3,000,000.00	Disclosure SEC source: 0001209191-22-055263 · doc4.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,642,202 F1 · balance_after: Consists of 1,500,000 shares of common stock held by Mr. Manning and 142,202 shares of common stock held by Mr. Manning jointly with his spouse. Read SEC document
October 13, 2022 Filed Oct 17, 2022 20:36 UTC	Candel Therapeutics, Inc. CADL · Entity 4969	GrantStock Option (Right to Buy) · Derivative	14,240	$0.00 Strike: $2.81	$0.00	Disclosure SEC source: 0001209191-22-053828 · doc4.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2032-10-13 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) October 13, 2023 or (ii) the date of the next Annual Meeting of Stockholders of the Company; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors of the Company or otherwise ceases to serve as a Director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.